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Abstract
Celastrol, a natural substance isolated from plant extracts used in traditional Chinese medicine, has been extensively
investigated as a possible drug for treatment of cancer, autoimmune diseases, and protein misfolding disorders. Although
studies focusing on celastrol’s effects in specific cellular pathways have revealed a considerable number of targets in a
diverse array of in vitro models there is an essential need for investigations that can provide a global view of its effects. To
assess cellular effects of celastrol and to identify target proteins as biomarkers for monitoring treatment regimes, we
performed large-scale quantitative proteomics in cultured human lymphoblastoid cells, a cell type that can be readily
prepared from human blood samples. Celastrol substantially modified the proteome composition and 158 of the close to
1800 proteins with robust quantitation showed at least a 1.5 fold change in protein levels. Up-regulated proteins play key
roles in cytoprotection with a prominent group involved in quality control and processing of proteins traversing the
endoplasmic reticulum. Increased levels of proteins essential for the cellular protection against oxidative stress including
heme oxygenase 1, several peroxiredoxins and thioredoxins as well as proteins involved in the control of iron homeostasis
were also observed. Specific analysis of the mitochondrial proteome strongly indicated that the mitochondrial association of
certain antioxidant defense and apoptosis-regulating proteins increased in cells exposed to celastrol. Analysis of selected
mRNA transcripts showed that celastrol activated several different stress response pathways and dose response studies
furthermore showed that continuous exposure to sub-micromolar concentrations of celastrol is associated with reduced
cellular viability and proliferation. The extensive catalog of regulated proteins presented here identifies numerous cellular
effects of celastrol and constitutes a valuable biomarker tool for the development and monitoration of disease treatment
strategies.
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Introduction
Plants used in traditional Chinese medicine are rich sources of
biologically active substances with potential therapeutic effects
towards many human diseases [1]. Root bark extracts of the
plant thunder of god vine (Tripterygium wilfordii)h a v eb e e nu s e d
in traditional Chinese medicine to treat fever, inflammation,
and various other health problems in man [2]. Celastrol is a
key constituent of thunder of god vine and possesses anti-
inflammatory activities that have shown promising therapeutic
e f f e c t si nm o d e l so fA l z h e i m e r ’ sd i sease [3], amyotrophic lateral
sclerosis [4], and rheumatoid arthritis [5,6]. Numerous studies
have furthermore shown that celastrol inhibits proliferation of
various cancer cell lines in vitro and suppresses tumor growth in
animal cancer models, as reviewed in [7,8]. Studies in a cellular
model of the inherited lysosomal storage disorder Gaucher’s
disease furthermore suggest that celastrol may be used to
ameliorate diseases caused by protein misfolding through
enhancing cellular protein folding and trafficking [9]. The
numerous indications of therapeutic effects in model systems
have stimulated investigations into the underlying molecular
mechanisms. Celastrol modulates the expression of genes
regulated through the (NF)-kB system [10,11]. This system
regulates multiple cellular activities related to the immune
system and its deregulation is linked to inflammatory diseases
and cancer [12]. Celastrol also triggers the heat shock response
[13], a stress response pathway that induces the expression of
heat shock proteins to protect cells from damage associated with
heat-induced protein misfolding [14]. Modulation of stress
response pathways and the resulting increased expression of
molecular chaperones in different cellular compartments may
explain why celastrol protects cells against an otherwise lethal
severe heat shock exposure [13] and improves intracellular
folding and processing of mutated proteins traversing the
endoplasmic reticulum [9]. It may seem controversial that a
single agent like celastrol can have therapeutic potential towards
several human diseases of different etiologies and it certainly
warrants further investigations into its molecular targets and
cellular effects. To provide a global view of the multiple effects
of celastrol we here report an extensive analysis of celastrol-
regulated proteins in cultured human lymphoblastoid cells based
on large-scale quantitative proteomics using mass spectrometry
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(SILAC) [15]. This analysis revealed a large number of celastrol-
regulated proteins, including many previously unrecognized
targets, and it significantly expands the current view of the
multifaceted effects of celastrol.
Results and Discussion
Overview of SILAC approach and quantified proteins
Stable isotope labeling with amino acids in cell culture (SILAC)
was used to differentially label the proteomes of two cell
populations, which subsequently were incubated in either
0.8 mM celastrol (treated) or in vehicle alone (dimethyl sulfoxide;
untreated) for 24 h (Figure 1). This dose was chosen because it
effectively increased the mRNA levels of HSPA1B (a well-known
celastrol targets encoding the cytosolic heat shock protein Hsp70)
and HSPD1 (encoding the mitochondrial heat shock protein 60
(Figure S1). Although the induction of HSPA1B peaked at celastrol
concentrations of approximately 5 mM a lower but still effective
concentration was preferred because of the well-known cytotoxic
effect of this drug. Following treatment, cell populations were
processed according to two different methodologies focusing on
the cellular proteome or the mitochondrial proteome specifically
(Figure 1). Relative changes in protein levels following celastrol
treatment (the treated to untreated ratio) were calculated from
nanoLC-MS/MS analysis of tryptic peptides using the MaxQuant
quantification algorithms [16].
The cellular proteome was defined from three replicated
experiments in which 2765 different proteins were quantified in
total (Table 1, and see Table S1 for full list). The 1779 proteins
common to all three experiments were designated the ‘‘cellular
core proteins’’ (Table 1 and full list in Table S2). The coefficient of
variation (CV) for the mean ratio of the cellular core proteins was
below 20% for more than 90% of the proteins, and below 10% for
more than 70% of the proteins (Figure S2). We found more up-
regulated than down-regulated cellular core proteins (Figure 2A).
One hundred and fifty-eight cellular core proteins were altered at
least 1.5 fold (listed in Table S3) and 112 of these were up-
regulated and 46 were down-regulated by celastrol.
In the mitochondrial proteome analysis, 498 different quantified
proteins were classified as mitochondrial by their listing in Human
Mitocarta [17] (Table 1 and full list in Table S4), and 375 of these
were quantified repeatedly (Figure 2B, see full lists in Tables S5
and S6). We defined these 375 proteins as the ‘‘mitochondrial core
proteins’’ and cross reference to the cellular proteome data
revealed that 253 of these were quantified in both approaches.
Our data clearly demonstrate that celastrol mediates substantial
changes to the proteome composition and the high number of
quantified proteins enables a solid and broad analysis of affected
biological pathways.
Overview of the functional classes of proteins affected by
celastrol
We assessed whether specific biological characteristics apply to
the celastrol-regulated proteins by using the functional annotations
of genes provided by the Gene ontology (GO) consortium [18].
Figure 1. Schematic overview of the SILAC-based experimental
design.
doi:10.1371/journal.pone.0026634.g001
Table 1. Overview of proteins quantified in cellular and mitochondrial proteome approaches.
Identified
Proteins*
Proteins with
quantitative data
¤ Core proteins
Mitocarta
proteins
?
Core mitocarta
proteins
Proteins changed at
least 1.5-fold
#
Cellular proteome 3342 2765 1779 482 314 158
Mitochondrial proteome 2404 1822 1083 498 375 33
*Excluding proteins judged as contaminants or identified in the reversed decoy database.
¤A quantitative SILAC protein ratio (treated/untreated) was calculated from at least two valid peptide ratio counts.
?Based on reference to human Mitocarta, a compendium of genes encoding proteins with solid evidence of mitochondrial origin.
#Inclusion criteria: t-test for mean ratio different from 1 (p,0.05), and mean ratio $1.5 or mean ratio #0.67.
doi:10.1371/journal.pone.0026634.t001
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cellular component, biological process, and molecular function.
Overall, the quantified proteins of the present study represent a
wide selection of cellular functions as illustrated by identification of
protein members in 24 of the 28 GO categories hosted at the level
directly below the general category ‘‘biological processes’’. The
GO categories in which we did not identify proteins have few
protein members or represent signaling and regulatory categories
Figure 2. Overall distribution of quantitative protein ratios within the cellular proteome study. (A) The mean treated/untreated ratios for
the 1779 cellular core proteins, including 314 of mitochondrial origin (according to human MitoCarta; marked with red cross). The figure insert shows
the frequency distribution of the protein ratios (x-axis legends define interval upper limits) and proteins up- or down-regulated at least 1.5 fold are
marked by oval circles. Protein ratios were calculated as the median of all SILAC peptide pair ratios identified for a given protein using normalized
peptide ratios. (B) The mean treated/untreated ratios for the 375 core mitochondrial proteins. Ratios for mitochondrial core proteins were calculated
using peptides intensity ratios that were normalized using only data from proteins listed in MitoCarta.
doi:10.1371/journal.pone.0026634.g002
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proteome analysis.
To assign functional properties specifically to the celastrol-
regulated proteins (cellular core proteins with ratio different from 1
by t-test), we performed a focused comparison of their GO
annotation with the annotation of all quantified proteins. Proteins
up-regulated by celastrol were overrepresented in 19 different
‘‘biological process’’ GO categories (Figure 3A), indicating that
many different biological pathways are affected by this drug. We
found overrepresentation of up-regulated proteins in GO categories
related to biotic and chemical stimuli. The GO analysis indicated
that celastrol-treated cells shift to a more catabolic state character-
ized by up-regulation of proteins involved in catabolic processes
(Figure 3A) and down-regulation of proteins involved in cellular
metabolism,biosynthesis,andgeneexpressionprocesses(Figure3B).
Finally, up-regulated proteins are also typically involved in cellular
Figure 3. Functional GO categories in which celastrol-regulated proteins are relatively overrepresented. (A) The distribution
frequencies for up-regulated proteins (red bars) into GO categories compared to the corresponding frequencies of the entire collection of proteins
quantified in the cellular proteome study (gray bars). Only Go categories in which a Pearson Chi-Square statistical test indicates a significant
overrepresentation of the up-regulated proteins are displayed. (B) Distribution of down-regulated proteins (green bars) into GO categories, analyzed
as described in (A).
doi:10.1371/journal.pone.0026634.g003
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intracellular transport processes (Figure 3A).
To analyze effects at the level of single proteins we manually
grouped the quantified proteins into functional classes (Tables 2
and 3) based on knowledge of their biological functions extracted
from the literature, the Uniprot protein knowledge database [19],
and the GO database. To increase the confidence level we only
focused on core proteins altered at least 1.5-fold. One hundred
and nine of these celastrol-regulated proteins clustered into the
functional pathways listed in Tables 2 and 3. All the 158 regulated
cellular core proteins and the 34 mitochondrial core proteins are
listed in Tables S3 and S6.
Celastrol up-regulated the cytoplasmic Hsp70 (HSPA1B) and
Hsp27 (HSPB1) heat shock proteins, which are well-documented
targets induced through activation of the heat shock response
[13,20]. We identified Hsp60 as a novel mitochondria-localized
heat shock protein up-regulated by celastrol (Table 2). The
promoter region of the HSPD1 gene encoding Hsp60 contains
regulatory regions for binding of transcription factors controlling
both the heat shock response [21] and the mitochondrial unfolded
protein response [22]. However, Hsp60 was most likely up-
regulated through heat shock response activation since we did not
observe increased ClpP protein level, which is a hallmark of
mitochondrial unfolded protein response activation [23].
A long list of up-regulated proteins involved in ER protein
quality control and handling activities such as folding, maturation,
and sorting of proteins destined for secretion was identified
(Table 2). These included the ER molecular chaperones GRP78
(HSPA5), Grp94 (HSP90B1), calnexin (CANX), calreticulin (CALR),
ERp29 (ERP29), multiple protein disulfide-isomerases, as well as
several glucosidase and glycosyltransferase enzymes involved in
adding and trimming of sugar residues on ER-traversing
glycoproteins. The cellular expression of several of these ER
proteins is under control of the ER unfolded protein response, a
well-described stress response activated by accumulation of
misfolded proteins and various other cell stressors. The ER
unfolded protein response signaling cascade initiates multiple
events to restore ER protein homeostasis and function, including
attenuation of protein translation to reduce the load of newly
synthesized proteins on the ER and transcriptional activation of
genes involved in restoring normal ER function, such as molecular
chaperones [24]. Celastrol-mediated activation of the ER unfolded
protein response may thus enhance the protein handling capacity
of the ER. In relation to this, celastrol has been shown to enhance
the ER trafficking and partially rescue the activity and function of
mutated variants of the glucocerebrosidase enzyme that normally
misfolds and are prematurely degraded [9]. This study further-
more documented that celastrol activated the ER unfolded protein
response in human fibroblast cells and increased expression of the
ER chaperone protein GRP78 but not of the ER chaperones
GRP94 and calreticulin [9], which we identified as celastrol-
regulated proteins in this study. Despite this discrepancy, both
Table 2. Functional categorization of up-regulated proteins.
Functional pathway Gene name
Ratio (treated/untreated)
[Group range]/median
Mediators of ER protein homeostasis,
ER protein quality control, and trafficking
ERAP1, UGCGL1, GANAB, LMAN1, PRKCSH, LMAN2, SURF4, STT3A,
HSP90B1, PDIA3, P4HB, PDIA6, PDIA4, DERL1, CANX, CALR, ERO1L,
RPN1, DDOST, HSPA5, ERP29, SEC11C, GCS1
[1.5 ; 2.0]/1.7
Protein quality control in other cell
compartments
HSPA1B, UCHL1, HSPB1, POMP, HSPD1 [1.6 ; 6.7]/1.9
Antioxidant defense HMOX1, PRDX1, TXN, TXNDC4, SELT, HYOU1, SEP15, PRDX4, IFI30 [1.5 ; 25.0]/1.9
Iron metabolism FTH1, PIR, PGRMC2, SFXN1, TFRC, BLVRB [1.5 ; 2.5]/1.6
Mitochondrial energy production and
metabolism
MTHFD1, GARS, MT-ATP6, LDHB, CYB5B, NNT, MT-CO2, COX4I1,
CYB5B, ATP5B, ATP5A1, ATP5L, ATP5H, COX4I1, UQCRC1, ATP5C1,
UQCRC2, UQCRQ, ATP1A1
[1.5 ; 2.9]/1.6
Cell death and proliferation CTSD, RHOA, PDCD4, PACAP, MS4A1, RTN3, VDAC1, LY75, BAX,
BCL2, TIRAP3, PDCD6, HK1
[1.5 ; 2.5]/1.8
Footnote: Proteins included fulfill the following criteria: Quantified in all three replicates with a mean ratio different from 1 (t-test; p,0.05), and up- or down-regulated
at least 1.5 fold by celastrol. Proteins are identified by their corresponding gene name. Proteins quantified in the mitochondrial proteome approach are marked by bold
font. Median ratio and range are given for groups of functionally-related proteins.
doi:10.1371/journal.pone.0026634.t002
Table 3. Functional categorization of down-regulated proteins.
Functional pathway Gene name
Ratio (treated/untreated)
[Group range]/median
Cell division CENPM, TBRG4, UBE2C, RCC2, KIF14 [0.2 ; 0.6]/0.5
DNA replication, transcription, repair,
and translation
RRM1, TFB2M, MSH2, ASF1B, EIF1, SHMT2, TSR1, PARP14,
GRSF1, POLD1, PRKDC, INTS3, RRM2, FEN1, PARP1, EIF5B
[0.5 ; 0.7]/0.6
Protein sorting EHD4, AP1G2, ABCF2, KPNA2, SRPR [0.5 ; 0.7]/0.6
RNA transport and structure XPO5, DDX3X, DDX21, SERBP1 [0.5 ; 0.6]/0.6
Proteins containing Iron/sulfur groups HN1, ISCA2, RRM2, HBA1 [0.3 ; 0.7]/0.5
See footnote in Table 2.
doi:10.1371/journal.pone.0026634.t003
Cellular Targets of Celastrol
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26634studies support the conceptual idea that the stress response-
modifying activity of celastrol may be exploited to ameliorate
diseases caused by misfolding of mutant proteins passing through
the secretory pathway.
Proteins involved in the cellular defense against oxidative stress
represented another well-defined group of celastrol-induced
proteins (Table 2) that included peroxiredoxins, thioredoxins,
and heme oxygenase 1 (HO-1). Peroxiredoxins catalyze the
reduction of peroxides and inhibit their potential damaging
reaction with other cellular constituents [25], whereas thioredoxins
participate in dithiol-disulfide exchange reactions and manage
redox-controlled activities [26]. Of special interest, peroxiredoxin
IV has recently been shown to localize to the ER where it
metabolizes hydrogen peroxide produced by the ER oxidase Ero1
during oxidative folding and thus protects cells against oxidative
damage [27]. It has been suggested that peroxiredoxin proteins
also function as molecular chaperones whose affinity for unfolded
target proteins is directly controlled by the oxidation status of its
redox-sensitive cysteines [28].
The HO-1 (HMOX1) was the single most (25 fold) highly up-
regulated protein in our study and this protein has recently also
been identified as a celastrol target in vascular smooth muscle cells
[29]. The HO-1 enzyme is responsible for the intracellular
oxidation of heme groups into free iron, carbon monoxide, and
biliverdin [30]. The expression of heme oxygenase 1 is induced by
several different stress stimuli such as increased levels of heme and
oxidants like hydrogen peroxide as well as by thiol-reactive
substances [31]. Increased heme oxygenase activity and the
associated production of free iron is functionally linked to another
group of up-regulated proteins identified in our study, namely
those involved in iron binding and storage (e.g., ferritin and pirin)
as well as in iron transport (e.g., sideroflexin-1 and transferring
receptor protein, see Table 2). These proteins collectively
participate in securing iron homeostasis and thus inhibit free iron
catalyzed production of highly damaging and reactive oxygen
species (ROS).
Another group of up-regulated proteins is collectively involved
in mitochondrial energy production and oxidative phosphoryla-
tion process (Table 2). Of special interest, several up-regulated
proteins are involved in apoptotic processes including the pro-
apoptotic protein BAX and the anti-apoptotic proteins Bcl-2
(Table 2). Other targets implicated in apoptosis regulation
included the VDAC1 and hexokinase 1 proteins. VDAC1 forms
pores in mitochondrial membranes from which apoptotic signaling
proteins such as cytochrome c are released [32], whereas binding
of hexokinase 1 to VDAC1 affects release of apoptotic proteins
and promotes cellular survival [33].
As also suggested by the gene ontology analysis (Figure 3B) the
down-regulated proteins typically are involved in cell division, as
well as in DNA replication, transcription, repair, and translation
(Table 3). Generally, these observations indicate that celastrol-
treated cells cut the resources used to general housekeeping
functions and proliferation while devoting more resources to
cytoprotection and stress handling.
Validation of MS-based quantification by Western
blotting
To validate the MS-based protein quantification, we performed
Western blot analysis of three selected proteins from treated and
untreated cells (Figure 4). A visual inspection of the Western blots
indicated a good correspondence to data from the MS-based
quantification both for the highly celastrol-induced proteins HO-1
(25-fold up-regulated in MS) and Hsp70 (6.7-fold), and for the
moderately induced Hsp60 protein (1.6-fold).
Transcriptional activation of selected genes involved in
stress responses and antioxidant defense
We investigated whether changes in protein levels were due
to transcriptional regulation by analyzing the mRNA levels of
selected genes by quantitative reverse-transcriptase PCR (RT-
PCR). We focused on genes involved in various cellular stress
responses, including HSPA5 and DDIT3/CHOP (ER unfolded
protein response), CLPP (mitochondrial unfolded protein response),
HMOX1 (antioxidant response), and HSPA1B, HSPD1 (heat shock
response). We used 1 mM celastrol to induce a strong transcriptional
response (see Figure S1) and measured mRNA levels after 8
and 24 h incubations. We found increased HSPA1B, HSPD1,
HSPA5, and HMOX mRNA levels (Figure 5A) corresponding to the
up-regulated proteins Hsp70, Hsp60, GRP78, and HO-1, respec-
tively (Table 2). This is in accordance with activation of the
heat shock response, ER unfolded protein response, and the
antioxidant response at the transcriptional level. Celastrol has
previously been reported to activate the heat shock response [13]
and the ER unfolded protein response [9] in mammalian cells.
A study in yeast cells (Saccharomyces cerevisiae) has furthermore
demonstrated that celastrol triggers the yeast antioxidant responses
through activation of the yeast antioxidant transcription factor
Yap1 [34].
In contrast, CLPP mRNA (Figure 5A) and protein levels (Table
S5) were not up-regulated, indicating that celastrol did not activate
the mitochondrial unfolded protein response. Celastrol increased
the levels of DDIT3 mRNA encoding the ER stress-activated and
apoptosis-regulating transcription factor CHOP [35].
We established that 8 h incubation was sufficient to induce the
selected stress genes (Figure 5A) and further studies showed that
4 h incubation was sufficient to significantly increase HSPA1B and
HSPD1 mRNA levels (data not shown). The target genes are thus
transcribed at a high level several hours prior to the time of
proteome analysis.
We noticed that transcript levels across all investigated genes
were consistently lower in celastrol-treated cells despite using the
same amount of total RNA in RT-PCR reactions. A lower mRNA
to total RNA ratio may suggest that celastrol generally inhibits
gene transcription. To address this further we re-analyzed the
quantitative RT-PCR data by normalizing the mRNA levels from
specific genes to the amount of total RNA instead of using a
reference gene (GAPDH). We found lowered mRNA level from
several genes involved in various cellular functions including
ACTB (encoding the beta-actin protein) (Figure 5B), ACADM, and
PGK1 (data not shown) in treated cells. Even the mRNA levels
from the highly induced HSPA1B and HSPD1 genes declined at
longer exposure times (Figure 5B). This indicates that celastrol,
Figure 4. Validation of MS-based protein quantification by
Western blot analysis of selected proteins. The soluble protein
extracted from cells treated with celastrol or vehicle alone (three cell
culturing experiments of each) were separated by SDS-PAGE, blotted
onto membranes, and detected using primary antibodies against
Hsp70, HO-1, or Hsp60, and fluorescently-labeled secondary antibodies.
doi:10.1371/journal.pone.0026634.g004
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generally inhibits gene transcription in a time- and dose-dependent
manner.
The celastrol dose (0.8 mM) used throughout the proteomics
studies was selected to give large expression level changes and to
facilitate identification of a high number of celastrol-regulated
proteins. Using the MTT metabolic activity assay, we found that
0.8 mM celastrol significantly reduced cellular viability. The
viability decreased in a concentration-dependent manner reaching
a maximum inhibitory effect at 1 mM with 24 h exposure time
(Figure 5C). We further established that 4 h exposure to 0.8 mM
was sufficient to lower cellular viability (Figure 5C).
Figure 5. Time- and dose-dependent effects of celastrol on transcriptional activation and cellular viability activity. (A) Transcript
levels from genes involved in the heat shock response, ER unfolded protein response, anti-oxidant response, and mitochondrial unfolded protein
response. The mRNA levels were measured by quantitative RT-PCR following incubation for 8 or 24 h in 1 mM celastrol. Relative mRNA levels were
normalized using GAPDH mRNA as a reference and presented relative to levels in untreated control cells. Data are mean of two independent
experiments (error bars show the range) and each cDNA was analyzed in triplicate PCR reactions. (B) Time- and dose-dependent inhibition of general
gene transcription. The HSPA1B, HSPD1, and ACTB mRNA levels in cells treated with 0.2, 0.5, or 1 mM celastrol for either 8 or 24 h were measured by
quantitative RT-PCR. The mRNA levels were normalized to the amount of total RNA used for the RT-PCR reaction and presented relative to levels in
untreated cells (arbitrary units, au). Data are mean of two independent experiments (error bars show the range) and each cDNA was analyzed in
triplicate PCR reactions. (C) Dose-dependent inhibition of MTT metabolic activity. The metabolic activity/viability following 24 h treatment with
varying celastrol concentrations was addressed by quantifying the cellular reduction of MTT into formazan. The amount of MTT reduced in a 4 h
period was measured spectrophotometrically by the absorbance Abs [A595–A655] of the formazan product. Each datapoint are the mean of three
experiments. Insert: Metabolic activity of cells exposed to 0.8 mM celastrol for 0, 1, 4, and 24 h. Data are mean (+/2SD) of three experiments.
doi:10.1371/journal.pone.0026634.g005
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in celastrol treated cells
The fact that several proteins were analyzed in both the cellular
proteome and the mitochondrial proteome prompted us to
investigate if celastrol affected mitochondrial association of a
selection of cellular proteins. Theoretically, proteins that associate
more with mitochondria in response to celastrol will display a
relatively larger treated/untreated ratio when analyzed in isolated
mitochondria (mitochondrial proteome experiments) than when
analyzed in the cellular proteome experiments. From cross
reference of the quantitative data for the 253 core proteins listed
in MitoCarta that were quantified in both the mitochondrial and
cellular proteome experiments, we identified more than 20
putative mitochondria translocating proteins (Figure 6). These
included antioxidant proteins such as peroxiredoxin 1 (PRDX1),
several ribosomal proteins, hexokinase 1 (HK1), BAX, and L-
lactate dehydrogenase B (LDHB) (Figure 6). Some of the putative
translocating proteins identified in this study have previously been
reported to associate with mitochondria under various physiolog-
ical conditions. Peroxiredoxin 1 has classically been categorized as
a cytosolic protein, but our data and those of Pagliarini [17]
suggest that this protein may associate with mitochondria under
specific cellular conditions. Hexokinase 1 can bind to the outer
mitochondrial membrane as part of a process that couples the
overall rate of glucose metabolism to the rate of mitochondrial
oxidative phosphorylation [36], and this association is involved in
the regulation of apoptosis and cell survival [33]. The pro-
apoptotic protein BAX translocates to mitochondria in response to
apoptotic stimuli [37].
Stress response activation in cell protection and
destruction
It is clear from this and previous studies [9,13,34] that celastrol
activates several stress response pathways and antioxidant systems.
This may enhance the cellular capacity to handle protein
misfolding and damages related to changes in the cellular redox
balance as well as offering increased cytoprotection towards acute
stress stimuli (Figure 7). However, sustained activation of stress
response pathways as e.g. associated with prolonged celastrol
exposure may be detrimental to cellular function and cause cell
death (Figure 7). Particularly, prolonged activation of the ER
unfolded protein response has been associated with apoptotic cell
death [24,38]. It has been suggested that the severity of the ER
stress determines whether cells survive or die and that this relies on
induction and differential stability of both pro-survival and pro-
apoptotic proteins [39]. Up-regulation of stress proteins and of
apoptosis-regulating proteins (such as BAX and Bcl-2) by celastrol
may thus reflect activation of both adaptive and cell destructive
pathways (Figure 7). Supported by the CHOP-activating activity
Figure 6. Increased mitochondrial association of selected
proteins in response to celastrol. The mean ratio of the 253 core
proteins shared by the mitochondrial proteome and the cellular
proteome data sets were extracted and presented in a scatter plot.
Selected proteins are labeled and putative translocating proteins are
enclosed by a circle.
doi:10.1371/journal.pone.0026634.g006
Figure 7. Celastrol effect model. A model illustrating how celastrol-mediated induction of stress response pathways may adapt cells to handle
protein misfolding stress and maintain homeostasis or activate cell destructive pathways.
doi:10.1371/journal.pone.0026634.g007
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by the fact that CHOP is believed to play a central role in
mediating apoptosis in response to prolonged ER stress [35], we
speculate that this transcription factor is fundamental for celastrol-
induced cell death. CHOP most likely mediates its effects by
activating downstream components such as the ER oxidase 1a
protein [41], which we also identified as a celastrol target.
The mechanism by which celastrol activates multiple cellular
pathways is still uncertain, but its ability to react with thiol groups
of regulatory proteins possibly plays a key role [34,42]. If the thiol-
reactivity of celastrol is more prevalent, one may speculate that it
interferes with disulfide bridge formation and correct folding of
non-native proteins. In the ER, where the flow of non-native
proteins is high, this may lead to accumulation of misfolded
proteins and activation of the ER unfolded protein response.
Whether this mechanism can explain the significant impact of
celastrol on the ER quality control system observed in this study is
unclear, but could be the subject of future studies.
Interestingly, a molecular mechanism responsible for the activity
of triptolide, another active compound derived from Tripterygium
wilfordii with potential anti-cancer activities, has recently been
reported. Triptolide modifies the activity of the transcription factor
TFIIthroughspecificandcovalentbindingtotheXPBsubunit [43].
One consequence of triptolide-XPB binding is general inhibition of
the RNA polymerase II mediated transcription, which resembles
the general reduction of the level of several mRNA observed in the
celastrol-treated cells of this study. Triptolide and celastrol both
have anti-proliferative and apoptosis-inducing activities, and are
therefore recognized as prime candidates for the development of
anti-cancer drugs from traditional Chinese herbal medicine [7,44].
However, triptolide and celastrol differ in the way heat shock gene
expression is affected. Triptolide inhibits the heat shock response by
impairing the transactivation function of the transcription factor
hsf1 [45], whereas celastrol activates the heat shock response
through activation of hsf1 [34]. Specific targets of celastrol that may
explain its anti-proliferative and apoptosis-inducing activities have
now been revealed in this (Figure 7) and other recent investigations,
see e.g. [10,40,46–48]. This may facilitate complete unraveling of
the molecular mechanism of celastrol but also pinpoint relevant
anti-cancer pathways that may be targeted more specifically by
other drugs. However, it is crucial that these targets and their
significance are validated in relevant in vivo cancer models before
initiation of clinical trails. These investigations should include
careful evaluation of pharmacokinetic parameters as we have
observed cell specific differences in celastrol dose response with
regard to both the toxicity and stress response induction (compare
Figures 5 and S3). Therapeutic usage of celastrol for cytoprotection
and improvement of cellular protein homeostasis requires that
severe anti-proliferative and cell-death activating effects can be
avoided through implementation of appropriate treatment regime.
One way to address this could be to investigate whether short bursts
of celastrol exposure may increase the protein handling capacity
sufficiently to enhance cellular clearance of misfolded proteins while
simultaneously avoiding unwanted side effects observed during
prolonged exposure (Figure 7).
In conclusion, we have provided an extensive biomarker catalog
of celastrol-regulated proteins and revealed multifaceted cellular
effects that can facilitate development and monitoration oftreatment
regimes based on celastrol or a more selective chemical derivative.
Materials and Methods
Sections of material and methods are described more detailed in
Text S1.
Cell culture and SILAC labeling
Lymphoblastoid cells (Coriell Institute for Medical Research
USA) were grown at 37uC in 95% humidified air and 5% (v/v)
CO2 in culture flasks (TPP). Culture media for SILAC labeling
were prepared according to guidelines in [49] using arginine and
lysine-depleted RPMI media (Pierce) supplemented with 10%
dialyzed fetal calf serum (Invitrogen), penicillin, streptomycin
(both Leo Pharmaceutical Products), and either 35 mg/l standard
arginine and 50 mg/l standard lysine (Invitrogen) or molar
equivalents of heavy isotopic arginine (Arg10: [
13C6,
15N4]-L-
Arginine) and lysine (Lys6: [
13C6] L-Lysine). Celastrol (Gaia
Chemical Corporation, USA) was added to a final concentration
of 0.8 mM to cells grown in heavy isotopic media for 6 cell-
doublings and equivalent amount of vehicle alone (dimethyl
sulfoxide) was added to cells grown in standard isotopic media.
Twenty-four hours later, celastrol-treated and untreated cells were
collected and proteins were extracted according to two different
protocols for analysis of either the cellular proteome or the
mitochondrial sub-proteome (see below and Figure 1).
Sample preparation for MS analysis
For analysis of the cellular proteome, equal amounts of protein
(see Text S1 for details on protein extraction and cell lysis) from
celastrol- and DMSO-incubated cells (20 mg from each) were
mixed at a 1:1 ratio and separated on a 12% sodium dodecyl
sulfate-bis-Tris polyacrylamide gel (SDS-PAGE) (Criterion XT;
BioRad). For analysis of the mitochondrial proteome, a mito-
chondria-enriched protein fraction was isolated (Qproteome
mitochondrial isolation kit, QIAGEN) from a 1:1 mixture of
treated and untreated cell populations, and a 30-mg aliquot was
separated by SDS-PAGE. Each lane in the gel was divided into 12
(mitochondrial proteome) or 16 (cellular proteome) samples. Each
sample was reduced for 10 min at 60uC in freshly prepared
50 mM tris(2-carboxyethyl)phosphine (TCEP), and then alkylated
in 100 mM iodoacetamide for 50 min in the dark. Following
two 15-min wash steps at 37uC in 50% acetonitrile (AcN),
each protein sample was digested with 0.6 mg trypsin (Trypsin
Gold; Promega) overnight at 30uC in 2.25 mM ammonium
bicarbonate (pH 8.2). Peptides were extracted from the gel
into protein low-binding tubes (Eppendorf) in two consecutive
steps, first with 80% AcN and 1% trifluoracetic acid (TFA), and
then with 100% AcN. Peptides were purified using PepClean
C-18 Spin Columns (Pierce) according to the manufacturer’s
protocol, lyophilized, and then re-dissolved in 40 ml MS buffer A
containing 0.4% acetic acid and 5% AcN before analysis by
nanoLC-MS/MS.
NanoLC-MS/MS analysis
The peptide mixtures were analyzed by liquid chromatography
(Easy nLC; Proxeon) coupled to mass spectrometry (LTQ-
Orbitrap; Thermo Fisher Scientific) through a nano-electrospray
source (Proxeon) essentially as described previously [50]. The
reverse phase separation column, 10 cm long and 75 mm in inner
diameter (G&T Septech), was packed with 3.5 mm Kromasil C18
particles (Eka Chemicals). The peptides were separated in a
100-min gradient of AcN in 0.4% acetic acid, starting with 5%
and ending with 36% AcN. MS detection was full scan (m/z
400–2000) with Orbitrap detection at resolution R=60,000
(at m/z 400) followed by up to four data-dependent MS/MS
scans with LTQ detection of the collision-induced dissociation
(CID) fragments of the most intense parent ions. Dynamic
exclusion of 25 s was used as well as rejection of a charge state
of +1.
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Mascot version 2.2.04 (Matrix Science) was used for peptide
identification and MaxQuant version 1.0.13.13 [16] for protein
identification and quantification. The MS data were searched
against IPI protein database version 3.52 containing 73,928
sequences and the same number of reversed sequences for false
discovery rate calculations (FDR). FDR was set to 0.01 for both
identification of peptides and proteins, corresponding well with the
identification of 36 proteins in the reversed database out of 3660
identified proteins in total. MS/MS mass tolerance was 0.5 Da.
Setting of trypsin digestion was cleavage at C-terminus of lysine
and arginine except before proline, and up to two missed cleavages
were accepted. Carbamidomethylation at cysteine residues was set
as fixed modification and oxidation of methionine was set as
variable modification. Only peptides with a minimum length of 6
amino acids were accepted and at least two peptides (and one
unique peptide) were required for protein identification. Calcula-
tions of quantitative SILAC protein ratios (treated/untreated)
were performed with Maxquant algorithms using standard settings
[16]. The resulting identification and quantification data are
listed in Tables S7 (protein data) and S8 (peptide data). A median
SILAC protein ratio was calculated from at least two valid peptide
ratio counts. Normalized protein ratios were calculated in
MaxQuant software using peptide ratios normalized within each
MS-run by setting the median of their logarithm to a value of
zero.
Gene ontology (GO) analysis
The distribution of the up- and down-regulated proteins
into GO categories was compared pairwise to the distribution
of all quantified members of the cellular proteome study
analyzed by Pearson Chi-Square statistics using the web-based
WeGo tool [51]. The analysis was restricted to the GO
categories hosted one and two levels below the general GO
category ‘‘biological process’’. The up- and down-regulated
proteins were defined as the cellular core proteins for which
the mean treated/untreated ratio was different from 1
(Student’s t-test at p,0.05).
Quantitative RNA analysis and Western blotting
RNA isolated from cells using the Total RNA isolation system
(Promega) was analyzed by quantitative reverse-transcriptase
PCR. RNA was transcribed into cDNA (Advantage RT for-PCR
Kit, Clontech) and analyzed by real-time PCR using Taqman
probe chemistry (Applied Biosystems). Relative quantification
with GAPDH as the reference gene was performed as previously
described [52] using the standard curve method with a calibra-
tion curve constructed from a 10–fold dilution series of pooled
cDNA.
For Western blotting, soluble proteins extracted from cells by a
detergent-based lysis buffer and centrifugation were transferred to
a polyvinylidene fluoride membrane (Millipore) using a semidry
blotting system (Bio-Rad). Proteins were detected by primary
antibodies against the proteins Hsp60 (H-3524; Sigma), HO-1
(OSA-110; stressgen), and Hsp70 (SPA810; Stressgen) using
infrared dye-labeled secondary antibodies (IRDye 800CW and
IRDye 680, LI-COR Biosciences) and an infrared imaging system
(Odyssey; LI-COR Biosciences).
Cellular viability assay
Cellular viability was addressed by the cellular reduction of
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay [53] as described previously [54].
Supporting Information
Figure S1 Celastrol dose response in lymphoblastoid
cells evaluated by HSPA1B and HSPD1 mRNA levels. The
dose-dependent induction of HSPA1B and HSPD1 mRNA
(encoding the Hsp70 and Hsp60 proteins, respectively) were
analyzed by quantitative RT-PCR using RNA isolated from
lymphoblastoid cells treated with varying celastrol concentrations
for 24 h. The relative mRNA levels from different genes were
normalized using GAPDH mRNA as reference and presented
relative to untreated control cells (t=0). Data are mean of two
independent experiments (errors bars show the range) and each
cDNA was analyzed in triplicate PCR reactions.
(TIF)
Figure S2 Variation between replicates in the cellular
proteome study. Coefficient of variation (values in 10%
intervals) for the quantitative ratios (treated/untreated) for the
1779 cellular core proteins illustrated by frequency histogram.
(TIF)
Figure S3 Cell specific celastrol toxicity and induction
of heat shock gene expression. (A) Comparison of the dose
dependent toxicity of celastrol in HEK293 and lymphoblastoid
cells measured by the MTT assay. Viability of cells incubated for
24 h in celastrol expressed relative to cells incubated in vehicle
alone (DMSO). (B) The inducible expression of markers of the
heat shock response (HSPA1B) and ER UPR (DDIT3) in HEK293
following 24 h incubation in celastrol analyzed by quantitative
RT-PCR as described in figure 5A legend.
(TIF)
Table S1 All quantified cellular proteins. This table lists
the treated/untreated quantitative ratios for all 2765 different
proteins quantified in at least one of three replicated cellular
proteome experiments.
(XLS)
Table S2 Cellular core proteins. This table shows selected
data (including the quantitative ratio (treated/untreated) for single
experiments, mean ratio, and descriptive statistic) for the 1779
cellular core proteins quantified repeatedly in three cellular
proteome experiments.
(XLS)
Table S3 Cellular core proteins 1.5 fold. This table lists the
158 cellular core proteins that are altered at least 1.5 fold.
(XLS)
Table S4 All mitochondrial proteins. This table lists the
treated/untreated quantitative ratio for the 498 quantified
proteins that are classified as mitochondrial by their listing in
Human MitoCarta.
(XLS)
Table S5 Mitochondrial core proteins. This table shows
selected data (including the quantitative ratio (treated/untreated)
for single experiments, mean ratio, and descriptive statistic) for the
374 mitochondrial core proteins quantified repeatedly in three
mitochondrial proteome experiments.
(XLS)
Table S6 Mito core proteins 1.5 fold. This table lists the 33
mitochondrial core proteins that are altered at least 1.5 fold.
(XLS)
Table S7 Protein evidence files. The table shows output
from Maxquant’s ‘‘Protein Groups’’ and contains data for all six
experiments, three cellular proteome experiments (D, E, and F),
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Numbers in the ‘‘Peptide ID’’ column refers to table S8.
(XLS)
Table S8 Peptide evidence files. This table shows peptide
evidence output from MaxQuant for identified proteins in table
S7.
(XLS)
Text S1 Supplementary materials and methods. Detailed
description of selected materials and methods.
(DOC)
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